• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Acorda Therapeutics, Inc. - Product Pipeline Review - H2 2011 Product Image

Acorda Therapeutics, Inc. - Product Pipeline Review - H2 2011

  • ID: 1999512
  • December 2011
  • 95 pages
  • Global Markets Direct

Acorda Therapeutics, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Acorda Therapeutics, Inc. - Product Pipeline Review - H2 2011” provides data on the Acorda Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Acorda Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Acorda Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Acorda Therapeutics, Inc. - Brief Acorda Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Acorda Therapeutics, Inc. human therapeutic division.
- Ov



List of Tables
List of Figures
Acorda Therapeutics, Inc. Snapshot
Acorda Therapeutics, Inc. Overview
Key Information
Key Facts
Acorda Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Acorda Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Acorda Therapeutics, Inc. – Pipeline Products Glance
Acorda Therapeutics, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Acorda Therapeutics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Acorda Therapeutics, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Acorda Therapeutics, Inc. – Drug Profiles
AC105
Ampydin
Chondroitinase Program
GGF2
rHIgM22
Acorda Therapeutics, Inc. – Pipeline Analysis
Acorda Therapeutics, I

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos